All In MedTech

Device Trial Radar · NCT07743697

Comparing Suture vs. Combined Closure Strategies for Large Blood Vessel Access in Patients Undergoing Transcatheter Aortic Valve Implantation (TAVI)

SEAL-TAVI - Suture vs combinEd Closure strAtegies in Large-bore Access After TAVI

Last checked: Nov 20, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 705 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

705

Planned (sponsor's estimate)

Start

Oct 1, 2026

Primary completion

Sep 2028

Study completion Sep 2028

Sponsor

Lead sponsor
University Hospital, Basel, SwitzerlandAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University Hospital, Zürich; University Heart Center Freiburg - Bad Krozingen; University Hospital Giessen and Marburg; University College Hospital Galway
First posted
Aug 4, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to compare two strategies for closing the main artery access site in adult patients undergoing transcatheter aortic valve implantation (TAVI) through a blood vessel in the leg (transfemoral access). The main questions it aims to answer are: Does using a single suture device lower the rate of access-related vascular complications compared to using a hybrid combination of a suture device and a plug-based closure device? How do the two closure strategies compare regarding bleeding complications, procedure time, and time to complete vessel sealing? Researchers will compare a single-suture closure strategy to a hybrid closure strategy (one suture plus one plug-based device) to see if using a single suture reduces vessel-related complications and improves patient safety after TAVI. Participants will: Undergo standard pre-procedure screening and TAVI via the main artery in the leg as part of routine medical care. Receive an initial single-suture placement before the large TAVI delivery system is inserted. Be evaluated after sheath removal for initial bleeding control; qualifying participants will then be randomly assigned (1:1) to either receive no additional device (single suture group) or receive a plug-based closure device (hybrid group). Have their heart and access site monitored during hospitalization, including laboratory checks and imaging prior to discharge. Complete a 72-hour safety and complication evaluation.

Conditions

  • Aortic Valve Stenosis
  • Postoperative Complications
  • Vascular System Injuries
  • Hemorrhage

Interventions

  • Single Suture-Based Vascular Closure DeviceDevice

    Transfemoral large-bore access site closure using a single pre-placed suture-based vascular closure device (Perclose ProGlide or Perclose ProStyle). The device is deployed at the beginning of the TAVI procedure prior to sheath insertion according to standard manufacturer instructions. Following procedure completion and main sheath removal, the single suture is tied down over a guide wire. Haemostasis is assessed immediately (Grade H0: dry/no bleeding, or Grade H1: minor oozing/bleeding controllable with manual compression). Final haemostasis is achieved via manual compression without additional plug adjuncts.

  • Extravascular Collagen Plug-Based Closure DeviceDevice

    Adjunctive deployment of an extravascular collagen plug-based vascular closure device (Angio-Seal 6F or 8F) following primary single-suture pre-placement. In patients achieving intra-operative Grade H0 (dry) or Grade H1 (minor oozing) haemostasis after primary suture tie-down, the Angio-Seal device is deployed over the retained safety guide wire into the common femoral artery access site to provide secondary extravascular mechanical sealing.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Access Site-Related Vascular ComplicationsTime frame: 30 days post-procedure

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Heart Center Basel, University Hospital Basel

    Basel, Canton of Basel-City, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.